Alessandro Giardino
Overview
Explore the profile of Alessandro Giardino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frigerio I, Bao Q, Bannone E, Giardino A, Spolverato G, Lorenzoni G, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682292
Objective: To build a Bayesian approach-based model to predict the success of surgical exploration post-neoadjuvant treatment. Background: Pancreatic cancer (PDAC) is best treated with radical surgery and chemotherapy, offering the...
2.
Pizzocaro E, Vella R, Frigerio I, Giardino A, Regi P, Scopelliti F, et al.
Nutr Health
. 2024 Nov;
:2601060241290281.
PMID: 39569447
Pancreatic cancer has an increasing incidence and prevalence trend. Its prognosis is negatively affected by poor/altered nutritional status. Therefore, nutritional interventions play a critical/pivotal role at any stage. Despite being...
3.
Vella R, Pizzocaro E, Bannone E, Gualtieri P, Frank G, Giardino A, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199582
This study aims to review existing literature on the effect of oral nutritional supplements (ONSs) during chemotherapy in older cancer patients. Electronic databases were searched for relevant studies up to...
4.
De Pastena M, Esposito A, Paiella S, Montagnini G, Zingaretti C, Ramera M, et al.
Surg Endosc
. 2024 Aug;
38(10):5881-5890.
PMID: 39164438
Background: This study analyzed the Quality of Life (QoL) and cost-effectiveness of laparoscopic (LDP) versus robotic distal pancreatectomy (RDP). Methods: Consecutive patients submitted to LDP or RDP from 2010 to...
5.
Boggi U, Kauffmann E, Napoli N, Barreto S, Besselink M, Fusai G, et al.
Ann Surg
. 2024 Feb;
280(1):56-65.
PMID: 38407228
Objective: The REDISCOVER consensus conference aimed at developing and validating guidelines on the perioperative care of patients with borderline-resectable (BR-) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Background: Coupled...
6.
Frigerio I, Capelli G, Chiminazzo V, Spolverato G, Lorenzoni G, Mancini S, et al.
Dig Surg
. 2023 Sep;
40(6):196-204.
PMID: 37699375
Introduction: Hepatic artery anomalies (HAA) may have an impact on surgical and oncological outcomes of patients undergoing pancreaticoduodenectomy (PD). Methods: Patients who underwent PD at our institution between July 2015...
7.
Bellotti R, Paiella S, Primavesi F, Jager C, Demir I, Casciani F, et al.
HPB (Oxford)
. 2023 Aug;
25(11):1411-1419.
PMID: 37563033
Background: Acinar cell carcinomas (ACC) belong to the exocrine pancreatic malignancies. Due to their rarity, there is no consensus regarding treatment strategies for resectable ACC. Methods: This is a retrospective...
8.
Lof S, Claassen L, Hannink G, Al-Sarireh B, Bjornsson B, Boggi U, et al.
JAMA Surg
. 2023 Jun;
158(9):927-933.
PMID: 37378968
Importance: Understanding the learning curve of a new complex surgical technique helps to reduce potential patient harm. Current series on the learning curve of minimally invasive distal pancreatectomy (MIDP) are...
9.
Bao Q, Frigerio I, Tripepi M, Marletta S, Martignoni G, Giardino A, et al.
Pancreatology
. 2023 Feb;
23(3):266-274.
PMID: 36841686
Background: The aim of this study is to evaluate the impact of major pathological response on overall survival (OS) in borderline resectable and locally advanced pancreatic ductal adenocarcinoma following neoadjuvant...
10.
DAlterio C, Giardino A, Scognamiglio G, Butturini G, Portella L, Guardascione G, et al.
Cells
. 2022 Nov;
11(21).
PMID: 36359736
Pancreatic ductal adenocarcinoma (PDAC) is currently the most deadly cancer. Although characterized by 5-20% of neoplastic cells in the highly fibrotic stroma, immunotherapy is not a valid option in PDAC...